Selecta Biosciences Inc. (SELB) Given Average Rating of “Strong Buy” by Brokerages
Selecta Biosciences Inc. (NASDAQ:SELB) has received an average broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Brokers have set a 1 year consensus price objective of $23.67 for the company and are forecasting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned Selecta Biosciences an industry rank of 109 out of 265 based on the ratings given to its competitors.
SELB has been the topic of a number of analyst reports. Stifel Nicolaus initiated coverage on Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $23.00 target price on the stock. Canaccord Genuity started coverage on Selecta Biosciences in a research note on Monday, July 18th. They issued a “buy” rating and a $20.00 price objective on the stock. Needham & Company LLC started coverage on Selecta Biosciences in a research note on Monday, July 18th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Tuesday, September 20th.
Shares of Selecta Biosciences (NASDAQ:SELB) opened at 16.53 on Wednesday. The firm has a 50 day moving average price of $14.07 and a 200-day moving average price of $13.39. Selecta Biosciences has a 12-month low of $10.26 and a 12-month high of $18.88.
A number of hedge funds and other institutional investors have recently made changes to their positions in SELB. Polaris Venture Management Co. V L.L.C. purchased a new position in shares of Selecta Biosciences during the second quarter valued at about $26,919,000. Perceptive Advisors LLC purchased a new position in shares of Selecta Biosciences during the second quarter valued at about $6,296,000. JPMorgan Chase & Co. bought a new stake in Selecta Biosciences during the second quarter worth $4,215,000. FMR LLC bought a new stake in Selecta Biosciences during the second quarter worth $3,997,000. Finally, Vanguard Group Inc. bought a new stake in Selecta Biosciences during the second quarter worth $1,679,000. 41.02% of the stock is currently owned by institutional investors.
About Selecta Biosciences
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.